ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of disease.
A range of ProteaseTag® based Point of Care tests are being developed for the routine monitoring of patients with chronic diseases, such as bronchiectasis, cystic fibrosis and COPD. Activity-based immunoassays are being developed for research use within academia and pharma. ProAxsis also offer a highly experienced team who can provide clinical trial support services in regard to the specific measurement of active proteases within clinical samples as well as target validation.
ProAxsis was founded in August 2013 by Professor Brian Walker and Dr Lorraine Martin, School of Pharmacy, Queen’s University Belfast. By September, ProAxsis had won the overall Northern Ireland Science Park’s 25K Award for entrepreneurialism and in February 2014, the first seed investment from partners NetScientific plc and QUBIS Ltd was secured. In September 2014, they were the first company in Northern Ireland to win a prestigious Horizon 2020 SME Instrument Award.